Kisspeptin-10 reverses obesity-diabetes effects by remodeling the gut-pancreatic axis in female mice
Kisspeptin-10 normalized body weight, blood glucose, and energy intake in obese diabetic female mice while increasing GIP/GLP-1 positive gut cells, restoring islet architecture, and promoting beta-cell proliferation through gut-pancreatic axis modulation.
Quick Facts
What This Study Found
Kisspeptin-10: normalized body weight, glucose, energy intake. Increased GIP+ and GLP-1+ gut cells. Restored villi length, crypt depth. Restored insulin area and glucagon radius. Increased beta-cell proliferation. Enhanced FSH and LH. 21-day treatment, 25 nmol/kg IP.
Key Numbers
How They Did This
High-fat diet obese diabetic female C57BL/6 mice. Kisspeptin-10 25 nmol/kg IP twice daily for 21 days. Immunohistochemistry for gut hormones and islet morphology. Hormonal profiling.
Why This Research Matters
This discovers a new metabolic function for kisspeptin that bridges reproductive and metabolic biology. By modulating both gut incretin cells and pancreatic beta-cells, kisspeptin could become a novel therapeutic target for obesity-diabetes.
The Bigger Picture
The reproductive-metabolic axis is increasingly recognized as a therapeutic target. Kisspeptin's ability to improve both gut incretin cell populations and pancreatic function suggests it could complement GLP-1 drugs rather than compete with them.
What This Study Doesn't Tell Us
Mouse study only. Female mice only. Short treatment (21 days). IP injection not practical for humans. Dose optimization not explored. Mechanism of gut cell effects unclear.
Questions This Raises
- ?Could kisspeptin analogues be developed for diabetes treatment?
- ?Does kisspeptin have similar metabolic effects in males?
- ?Would combining kisspeptin with GLP-1 drugs provide synergistic metabolic benefits?
Trust & Context
- Key Stat:
- Beta-cell proliferation increased Kisspeptin-10 not only normalized weight and glucose but promoted pancreatic beta-cell growth—a mechanism that could address the root cause of diabetes
- Evidence Grade:
- Preclinical mouse study with comprehensive gut and pancreas analysis. Novel finding with strong data.
- Study Age:
- Published in 2025.
- Original Title:
- Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.
- Published In:
- Biomolecules, 15(11) (2025)
- Authors:
- Sridhar, Ananyaa, Khan, Dawood(2), Muthukumar, Rithiga, Sampathkumar, Swetha, Irwin, Nigel, Flatt, Peter R, Moffett, R Charlotte
- Database ID:
- RPEP-13667
Evidence Hierarchy
Frequently Asked Questions
What is kisspeptin?
Kisspeptin is a neuropeptide best known for controlling puberty and reproduction. This study reveals it also has powerful metabolic effects—normalizing weight, blood sugar, and appetite in obese diabetic mice while improving the health of insulin-producing cells in the pancreas.
Could kisspeptin treat diabetes?
This study provides early evidence that it might. Kisspeptin-10 not only controlled weight and blood sugar but actually promoted the growth of insulin-producing beta-cells—addressing a fundamental problem in diabetes. However, this was in mice only; human studies are needed.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13667APA
Sridhar, Ananyaa; Khan, Dawood; Muthukumar, Rithiga; Sampathkumar, Swetha; Irwin, Nigel; Flatt, Peter R; Moffett, R Charlotte. (2025). Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.. Biomolecules, 15(11). https://doi.org/10.3390/biom15111591
MLA
Sridhar, Ananyaa, et al. "Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.." Biomolecules, 2025. https://doi.org/10.3390/biom15111591
RethinkPeptides
RethinkPeptides Research Database. "Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effe..." RPEP-13667. Retrieved from https://rethinkpeptides.com/research/sridhar-2025-kisspeptin10-ameliorates-obesitydiabetes-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.